KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Kymera Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$108.07+3.29 (+3.14%)
Close on Oct 19, 2026
- Market cap
- $10.61B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$48.24 (+80.63%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Kymera Therapeutics, Inc. grew revenue 134.8% to $105.00M over the twelve months to Jun 30, 2026. Free cash flow was -$237.96M.
Revenue
$105.00M
+134.8% vs. a year earlier
Operating income
-$350.18M
TTM Q2 2026
Free cash flow
-$237.96M
TTM Q2 2026
EPS, diluted
-$3.24
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $10.61B
- P/E ratio
- –
- Price to sales
- 101.05
- Price to book
- 7.03
- Dividend yield
- –
- Free cash flow yield
- -2.24%
Fundamentals
- Revenue
- $105.00M
- Net income
- -$299.60M
- EPS, diluted
- -$3.24
- Free cash flow
- -$237.96M
- Book value per share
- $15.37
- Diluted shares
- 98M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$105.00M+134.8% YoY
Gross profit
$0
Operating income
-$350.18M
Net income
-$299.60M
EPS, diluted
-$3.24
Free cash flow
-$237.96M
Reported periodTrailing twelve months